Tianjin

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma5 trials
• Asthma2 trials
• Hepatitis B2 trials
• Colorectal cancer1 trial
• Osteoarthritis1 trial
• Primary biliary cholangitis1 trial

Phase

• Phase 310 trials
• Phase 22 trials

Status

• Active, not recruiting6 trials
• Recruiting3 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• GlaxoSmithKline12 trials

Running trials

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Shuhui Deng (principal investigator)

• Recruiting

  Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

  NCT06979323· Phase 3· GlaxoSmithKline· Source

  Contact: Jie Cao (principal investigator)

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Wang Huaqing (principal investigator)

• Active, not recruiting

  Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT06868654· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Linerixibat Long-term Safety, and Tolerability Study

  NCT04167358· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT04246047· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04162210· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Colorectal cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Terminated

  A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

  NCT05838742· Phase 2· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

  NCT04937387· Phase 3· GlaxoSmithKline· Source